Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is <u>only effective</u> for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

- 1. Name of the Principal Investigator with appropriate contact information
- 2. A descriptive title of the potential application
- 3. Brief description of the project
- 4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-Al-21-001.html

MGH LOI Deadline: 4/12/21 NIH LOI Deadline: 5/15/21

NIH Application Deadline: 6/15/21

The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

2. Human Immunology Project Consortium (HIPC) (U19 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-Al-20-079.html

MGH LOI Deadline: 4/13/21 NIH LOI Deadline: 5/4/21

NIH Application Deadline: 6/4/21

This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPCsupported data and meta-data through public portals such as ImmPort. A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.

3. Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-080.html

MGH LOI Deadline: 4/13/21 NIH LOI Deadline: 5/4/21

NIH Application Deadline: 6/4/21

The goal of this FOA is to support a Coordinating Center for the Human Immunology Project Consortium (HIPC) program. The HIPC program, supported through a separate FOA, will consist of 5-8 multi-project cooperative agreement (U19) awardees that will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The HIPC Coordinating Center supported by this FOA will be responsible for: coordinating cross-HIPC data integration, analysis, and visualization; developing and maintaining a public HIPC website and knowledgebase to support cross-HIPC data analysis and visualization; and fostering collaborations amongst HIPC-funded investigators by managing the HIPC subcommittees and an Infrastructure and Opportunity Fund to support collaborative studies.

4. Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-009.html

MGH LOI Deadline: 4/13/21 NIH LOI Deadline: 5/10/21

NIH Application Deadline: 6/10/21

This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin and to develop a catalog of VOCs as distinct signatures

for at least 20 human diseases and conditions. These sensing devices must be able to associate VOC patterns using artificial intelligence to patients with various conditions for diagnostic purposes along with capabilities to incorporate and integrate vital signs. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology, Gas Chromatography (GC) or any sensing technology able to detect VOC patterns associated with disease. This new program is called SCENT, which stands for Screening for Conditions by E-Nose Technology.

To ensure project success, this FOA requires multidisciplinary collaborations and a team science approach. Groups may include a combination of the following: Biomedical engineers, material scientists, biosensing experts, software engineers, chemists, clinicians, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.

5. Program to Advance the Career Development of Scientists from Diverse Backgrounds Conducting Nutrition, Obesity, Diabetes, and Related Research (U24 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-034.html

MGH LOI Deadline: 4/19/21 NIH LOI Deadline: 5/17/21

NIH Application Deadline: 6/17/21

The purpose of this Funding Opportunity Announcement is to enhance the diversity of the research workforce who are available to successfully compete for independent research funding from NIH in the areas of nutrition, obesity, diabetes, and related conditions. This program will establish a consortium providing professional development, mentoring, networking, pilot and feasibility funds, and other opportunities designed to advance the career development of post-doctoral scholars and early career faculty from diverse backgrounds, including those from groupsnationally underrepresented in biomedical and behavioral research, who intend to pursue a research career focused on nutrition, obesity, diabetes, and/or related conditions. The program will be administered through research institutions with substantial existing NIH funding within the research mission of NIDDK.

6. Maximizing Access to Research Careers (T34)
https://grants.nih.gov/grants/guide/pa-files/PAR-21-147.html

MGH LOI Deadline: 4/20/21 NIH Application Deadline: 5/26/21

The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-intensive institutions (i.e., those with an average of NIH Research Project Grant funding greater than or equal to \$7.5 million total costs over the last 3 fiscal years).

This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

7. Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34) https://grants.nih.gov/grants/guide/pa-files/PAR-21-146.html

MGH LOI Deadline: 4/21/21 NIH Application Deadline: 5/26/21

The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than \$7.5 million total costs over the last 3 fiscal years).

This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

8. New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-001.html

MGH LOI Deadline: 5/04/21 NIH LOI Deadline: 6/08/21

NIH Application Deadline: 7/08/21

The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural - extramural collaborations to develop additional physical modules that will enhance the platform's capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.

9. Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-TW-21-002.html

MGH LOI Deadline: 5/11/21 NIH LOI Deadline: 6/08/21

NIH Application Deadline: 7/08/21

This Funding Opportunity Announcement (FOA) solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health

(GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research training must be harmonized with a linked application for related research under RFA-TW-21-001 "Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)". This research training FOA is intended to support research training of LMIC investigators, provide mentored research training opportunities in the partner LMIC, and strengthen the capacity of the partner LMIC institution to conduct environmental and occupational health research.

This Funding Opportunity Announcement (FOA) allows appointment of Trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

10. Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 – Clinical Trial Not Allowed) – NEW!

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-002.html

MGH LOI Deadline: 6/09/21 NIH LOI Deadline: 7/09/21

NIH Application Deadline: 8/09/21

The purpose of this Funding Opportunity Announcement (FOA) is to support a coordinating center (CC), which will coordinate research efforts across the NIDA funded longitudinal cohorts that address emerging and high priority research on HIV/AIDS in the context of substance use and substance use disorders (SUD). The coordinating center will serve as 1) a national data and specimen resource that harmonizes and collects data and biological samples from the NIDA cohorts and affiliated studies, and enables additional research efforts through virtual repositories; 2) a facilitator of current and future research at the intersection of HIV and substance use and SUD; and 3) the central hub for organizing and enabling communication within and outside the NIDA cohort studies program, including annual meetings, advisory and scientific oversight committees.